Streetwise Live! Presents Algernon Pharmaceuticals on 01/27/2022. Learn More

Sector Expert: Jay Silverman

Image: Jay Silverman

Jay Silverman has been a biotechnology and pharmaceuticals analyst for more than 25 years. In 2000, he was ranked #1 in biotechnology by The Wall Street Journal's Best on the Street annual analyst survey, in addition to being a "Home-Run Hitter" for stock selection. As an analyst, he was frequently quoted in The Wall Street Journal, TIME, Fortune and featured on CNBC and CNN. From 2010-2012, Silverman was vice president, business development for Thorne Research, a leading natural products company. From 2007-2010, he was vice president, strategic fevelopment for Diversified Natural Products, which merged with Thorne Research in June 2010. From 2003-2005, Silverman was a partner in charge of healthcare investments at Colonial Fund LLC, a New York-based hedge fund. Silverman is also president of COLS Consulting. From 1997-2001, he was a managing director, senior biotechnology analyst for Robertson, Stephens. From 1992-1997, Silverman was senior biotech and medical technology analyst for Schroeder Wertheim. From 1987-1992, he was senior biotechnology and pharmaceuticals analyst for Nomura Research Institute. He graduated from the University of Pennsylvania's Wharton School in 1987 with a bachelor's degree in economics/finance.

Recent Interviews

Fallen Biotech Angels to Arise: John McCamant and Jay Silverman of the Medical Technology Stock Letter (9/16/15)

It's all about data for John McCamant and Jay Silverman of the Medical Technology Stock Letter, and right now it's festival time as we approach the busy season of market-moving catalysts and milestones. From now until December, biotech investors will be focused on the press releases, webinars and scientific presentations that serve as a vitality tonic for the entire biotech industry. In this interview with The Life Sciences Report, McCamant and Silverman give a detailed picture of their growth theories on six biotech stocks that could reap many multiples on invested capital over the next few years.

Due to permission requirements, not all quotes are shown.